Chester County News and Community Website
WILMINGTON, DE — Japan’s Ministry of Health, Labour and Welfare has approved Minjuvi (tafasitamab) in combination with lenalidomide for adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), providing …
Japan Approves Incyte Lymphoma Therapy, Expanding DLBCL Options Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported updated early-stage clinical trial data showing its experimental antibody INCA033989 produced rapid and durable responses in patients with myelofibrosis and essential thrombocythemia, supporting …
Incyte Antibody Shows Disease-Modifying Potential in Blood Cancers Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) reported Phase III trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death …
Incyte Trial Data Support New First-Line Approach in Lymphoma Read More WILMINGTON, DE — Incyte has agreed to acquire Vega Therapeutics for $1.25 billion upfront in a deal that would add a late-stage treatment candidate for von Willebrand disease to the …
Incyte Agrees to $1.25 Billion Acquisition to Expand Hematology Pipeline Read More WILMINGTON, DE — Mirum Pharmaceuticals (Nasdaq: MIRM) and Incyte (Nasdaq: INCY) are set to present pivotal Phase 2 clinical data for investigational fibrodysplasia ossificans progressiva (FOP) treatment zilurgisertib this week, …
Mirum, Incyte Advance FOP Drug as FDA Review Continues Read More WILMINGTON, DE — Incyte reported Phase 3 trial results showing that adding tafasitamab and lenalidomide to the standard R-CHOP regimen reduced the risk of disease progression or death in patients …
Incyte Study Shows Lymphoma Regimen Extends Progression-Free Survival Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) is scheduled to present at the Goldman Sachs 47th Annual Global Healthcare Conference on June 9, providing investors with an opportunity to hear updates …
Incyte to Present Strategy Update at Goldman Sachs Healthcare Conference Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) is expanding its partnership with biotechnology software firm Genesis Molecular AI in a deal worth $120 million upfront, giving the company broader access to …
Incyte Deepens AI Drug Discovery Bet in $120 Million Deal Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) has entered a strategic collaboration with Edison Scientific to integrate an artificial intelligence platform across portions of its drug discovery and development operations, reflecting …
Incyte Expands AI Role in Drug Discovery Read More WILMINGTON, DE — Incyte (Nasdaq: INCY) will present new clinical and preclinical data across its hematology and oncology pipeline at the 2026 European Hematology Association Congress, as the drugmaker seeks …
Incyte Advances Lymphoma, MPN Programs Ahead of EHA Data Read More